Boston Scientific Corporation vs Invesco DB Oil Fund — how do they compare? Boston Scientific Corporation trades at $43.2 (market cap $66.37B), while Invesco DB Oil Fund trades at $20.16. The key difference: Invesco DB Oil Fund is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | DBO | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Commodities - Energy |
52-Week High | $108.14 | $23.80 |
52-Week Low | $42.63 | $11.98 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
DBO is trading at $19.59, up 8.47% with strong bullish momentum driven by escalating Middle East tensions that are boosting oil prices. Technical indicators show a bullish trend with support at $19 and resistance at $20, though RSI suggests potential overbought conditions. The stock benefits from geopolitical events that typically drive energy sector performance.
The outlook remains positive as oil price strength translates to potential revenue growth for US energy companies. Key risks include geopolitical volatility and potential supply disruptions. Analyst sentiment appears constructive given the favorable oil market dynamics, though fundamental metrics require verification from recent SEC filings.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →